Dechra Pharmaceuticals falls despite strong revenue and profits growth

By
0 mins. to read
Dechra Pharmaceuticals falls despite strong revenue and profits growth
Master Investor Magazine 40 cover

Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

FTSE 250 veterinary drug manufacturer Dechra Pharmaceuticals (LON:DPH) announced that revenues for the first six months of the year rose by 13.3% to £407.1 million. Despite this, shares in the company dropped by 14.23% to 2,676p (as of 11:50 BST) as the firm warned about future taxation and geopolitical risks including a hard Brexit and tighter Iranian sanctions.

Underlying profits rose by 21.7% to £93.7 million as both the European and North American arms performed strongly as the group adjusted to increased corporate consolidation among veterinary practices across the UK and Northern Europe.

Management believe that the company has made a strong start to the current year and said that their strategy and flexibility will allow them to outperform their industry.

 

 

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

YOUR FREE INVESTMENT MAG

Get real investment insights from some of the best minds in the business - with our free Master Investor Magazine.